We are live on
!
Find out more
RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$810M
1-Year Est. Return
30.2%
This Fund
S&P 500
This Quarter
Est. Return
+14.22%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$949M
AUM Growth
+$37.8M
(+4.1%)
Cap. Flow
-$30.5M
Cap. Flow
% of AUM
-3.21%
Top 10 Holdings %
Top 10 Hldgs %
31.29%
Holding
98
New
10
Increased
21
Reduced
41
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$34M |
| 2 |
Zimmer Biomet
ZBH
|
+$18.8M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$14.6M |
| 4 |
Intuitive Surgical
ISRG
|
+$10.3M |
| 5 |
Procept Biorobotics
PRCT
|
+$9.22M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$21.9M |
| 2 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
+$8.61M |
| 3 |
Tenet Healthcare
THC
|
+$8.54M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$8.33M |
| 5 |
UnitedHealth
UNH
|
+$7.82M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.42% |
| 2 | Industrials | 0.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IGMS
76
DELISTED
IGM Biosciences
IGMS
| $1.85M | 0.19% |
200,000
+105,000
| +111% | +$1.18M |
|
77
INmune Bio
INMB
$58.8M
| $1.62M | 0.17% |
+178,284
| New | +$1.43M |
|
78
Allogene Therapeutics
ALLO
$725M
| $1.49M | 0.16% |
300,000
| – | – |
|
79
TG Therapeutics
TGTX
$7.52B
| $1.37M | 0.14% |
+55,000
| New | +$1.42M |
|
|
MRSN
80
DELISTED
Mersana Therapeutics
MRSN
| $1.32M | 0.14% |
16,000
+2,000
| +14% | +$293K |
|
|
EPIX
81
DELISTED
ESSA Pharma
EPIX
| $963K | 0.1% |
356,500
| – | – |
|
82
Rigel Pharmaceuticals
RIGL
$778M
| $327K | 0.03% |
25,383
-90,376
| -78% | -$1.22M |
|
|
83
Thermo Fisher Scientific
TMO
$222B
| $261K | 0.03% |
500
-40,500
| -99% | -$21.9M |
|
84
Agilon Health
AGL
$1.63B
| – | – |
-3,600
| Closed | -$2.1M |
|
|
ESPR
85
DELISTED
Esperion Therapeutics
ESPR
| – | – |
-900,000
| Closed | -$1.5M |
|
86
Nkarta
NKTX
$176M
| – | – |
-200,000
| Closed | -$680K |
|
87
NovoCure
NVCR
$2.02B
| – | – |
-45,000
| Closed | -$2.62M |
|
88
Pfizer
PFE
$154B
| – | – |
-190,000
| Closed | -$7.67M |
|
89
Phreesia
PHR
$769M
| – | – |
-120,000
| Closed | -$3.7M |
|
90
Insulet
PODD
$9.91B
| – | – |
-24,000
| Closed | -$7.61M |
|
91
Rapid Micro Biosystems
RPID
$85.2M
| – | – |
-127,152
| Closed | -$165K |
|
|
SGMO
92
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| – | – |
-314,157
| Closed | -$534K |
|
93
Stereotaxis
STXS
$143M
| – | – |
-493,618
| Closed | -$953K |
|
|
SILK
94
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| – | – |
-221,255
| Closed | -$8.61M |
|
|
SGEN
95
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-41,000
| Closed | -$8.33M |
|
|
VRAY
96
DELISTED
ViewRay, Inc.
VRAY
| – | – |
-1,000,000
| Closed | -$3.32M |
|
|
ISEE
97
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-280,000
| Closed | -$6.66M |
|
Similar funds
ACM
AR
KCP
BCM
RIM
GCM
CL
AF
Rhenman & Partners Asset Management's Q2 2023 Portfolio in Review
As of Q2 2023, Rhenman & Partners Asset Management held 98 positions worth $949M, up 4.1% from $911M the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Rhenman & Partners Asset Management withdrew a net $30.5M in Q2 2023, closing 15 positions and reducing 41 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $8.61M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier, followed by Industrials.
Against the trend, Rhenman & Partners Asset Management opened a new position in Eli Lilly worth $38M.
- Rhenman & Partners Asset Management's largest Q2 2023 buy was Eli Lilly: 81,000 shares worth $38M.
- Rhenman & Partners Asset Management added most to BioMarin Pharmaceuticals in Q2 2023, an estimated $14.6M increase.
- Rhenman & Partners Asset Management's biggest Q2 2023 reduction was Thermo Fisher Scientific, cutting an estimated $21.9M.
- Rhenman & Partners Asset Management fully exited Silk Road Medical, Inc. Common Stock in Q2 2023, selling an estimated $8.61M.
- Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $949M portfolio in Q2 2023.
- Rhenman & Partners Asset Management opened 10 new positions and closed 15 in Q2 2023.
- Rhenman & Partners Asset Management's portfolio value rose 4.1% quarter-over-quarter to $949M.
Based on Rhenman & Partners Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.